What About A ‘Country of Origin’ Label for Pharmaceuticals?
By Kenneth Rapoza, CPA Industry Analyst The FDA hasn’t inspected nearly 1,000 overseas labs making drugs for the US market due to the pandemic. But
By Kenneth Rapoza, CPA Industry Analyst The FDA hasn’t inspected nearly 1,000 overseas labs making drugs for the US market due to the pandemic. But
By Kenneth Rapoza, CPA Industry Analyst By most measures, China is preparing for the future. The 2021 Government Work Report is a reminder of what
By Kenneth Rapoza, CPA Industry Analyst As states lift lockdowns, pent up demand from consumers and businesses are driving imports. But the data shows that
By Kenneth Rapoza, CPA Industry Analyst The Government Accountability Office says more can be done to stop forced labor goods from coming into US ports.
By Kenneth Rapoza, CPA Industry Analyst Anthony Blinken: the US will build a “foreign policy for the middle class.” This will require a massive reindustrialization
By Kenneth Rapoza, CPA Industry Analyst President Biden’s Executive Order on critical supply chains and their resiliency needs special attention to be placed on the
By Kenneth Rapoza, CPA Industry Analyst Shipping companies are preferring to send empty containers to Asia, in order to offload them and fill them with
By Kenneth Rapoza, CPA Industry Analyst With the exception of scolding China and threatening fines against companies doing business in Xinjiang — home to the
By Kenneth Rapoza, CPA Industry Analyst Following her Senate hearing, future USTR Katherine Tai responds to written questions. Here’s how she handled questions on the
By Kenneth Rapoza, CPA Industry Analyst China is increasing its coal capacity at a time when the US and Europe are increasingly worried about climate